News

TED is a rare, serious, progressive and vision-threatening autoimmune disease, and is associated with proptosis (eye bulging), diplopia (double vision), blurred vision, pain and facial disfigurement that can

The company has unveiled the topline results from its global phase 111 Luster-1 and Luster-2 studies evaluating the efficacy and safety of the investigational oral, once-daily, DP2 receptor

These new data, from a primary analysis of the FeDeriCa study, will be presented in a spotlight session at 07.00 CST today at the 2019 San Antonio Breast

It is estimated that about 8 percent of patients with DMD have this mutation. “The FDA recognizes the urgent need for new medical treatments for serious neurological disorders

According to 3M, the total consideration includes cash, an interest-bearing security, and a 17% non-controlling stake in the new company that will hold the divested drug delivery business.

In an IIT study conducted by Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, the oral presentation highlighted the impressive safety, efficacy and persistence

The primary endpoint of objective response rate (ORR), confirmed by independent central review, was 60.9% with trastuzumab deruxtecan monotherapy (5.4mg/kg). Patients had a median of six prior therapies

The overall adverse event rate was comparable between tralokinumab and placebo during the trials, said the company. Tralokinumab is an investigational and fully human monoclonal antibody, which neutralises

According to the US biopharma company, lebrikizumab is a monoclonal antibody that can bind with very high affinity with the Interleukin 13 (IL-13) cykotine. Through this mechanism, the